San Diego-based Arena Pharmaceuticals (NASDAQ: [[ticker:ARNA]]), the developer of treatments for obesity and diabetes, said today that Johnson & Johnson has terminated a partnership to co-develop a diabetes drug after reviewing results from a Phase I clinical trial. Full rights to the drug, APD597, will go back to Arena. The drug, an oral pill, is designed to stimulate a target called GPR119.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
